BiomX Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$PHGE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $PHGE alert in real time by email
false 0001739174 0001739174 2024-09-26 2024-09-26 0001739174 PHGE:UnitsEachConsistingOfOneShareOfCommonStock0.0001ParValueAndOneWarrantMember 2024-09-26 2024-09-26 0001739174 PHGE:CommonStock0.0001ParValueMember 2024-09-26 2024-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 26, 2024

 

BiomX Inc.
(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-38762   82-3364020
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

708 Quince Orchard Rd, Suit 205

Gaithersburg, MD

  20878
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (844) 972-0500

 

n/a
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant   PHGE.U   NYSE American
Common Stock, $0.0001 par value   PHGE   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

BiomX Inc., or the Company, from time to time, presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. On September 26, 2024, the Company posted an updated corporate slide presentation in the “Investors” portion of its website at www.biomx.com. A copy of the slide presentation is furnished pursuant to Item 7.01 as Exhibit 99.1 hereto. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit   Description
99.1   Investor Presentation dated September 26, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL documents)

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOMX INC.
     
September 26, 2024 By: /s/ Jonathan Solomon
    Name:  Jonathan Solomon
    Title: Chief Executive Officer

 

 

2

 

 

Get the next $PHGE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PHGE

DatePrice TargetRatingAnalyst
11/16/2021$16.00 → $13.00Buy
Chardan Capital
10/19/2021$28.00 → $16.00Buy
Chardan Capital
10/18/2021$20.00 → $10.00Buy
HC Wainwright & Co.
More analyst ratings

$PHGE
Press Releases

Fastest customizable press release news feed in the world

See more
  • BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

    NESS ZIONA, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification from the NYSE American LLC ("NYSE American"), dated December 10, 2024, stating that the Company has regained compliance with all NYSE American LLC continued listing standards. Specifically, the Company has resolved prior listing deficiencies raised on May 23, 2024, by NYSE American and set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide (the "Company Guide"). NYSE American confirmed

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

    BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to host conference call and webcast today at 8:00AM ET NESS ZIONA, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE, the "Company" or "BiomX")), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announces financial results for its third quarter ended September 30, 2024, and provide

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

    NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PHGE
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PHGE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PHGE
SEC Filings

See more

$PHGE
Leadership Updates

Live Leadership Updates

See more
  • BiomX Announces the Appointment of Susan Blum to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

    $PHGE
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Telum Therapeutics appoints Dr. Subhendu Basu as CEO

    Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PHGE
Financials

Live finance-specific insights

See more
  • BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

    BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025 BX004 Phase 2b study in Cystic Fibrosis (CF) is now expected to report topline results in H1 2026 following resolved manufacturing delays Company to host conference call and webcast today at 8:00AM ET NESS ZIONA, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE, the "Company" or "BiomX")), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announces financial results for its third quarter ended September 30, 2024, and provide

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

    NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

    BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading phage therapy pipeline Recent stockholder vote approves conversion of Series X Non-Voting Convertible Preferred Stock (issued upon merger with Adaptive Phage Therapeutics and concurrent financing) to BiomX's common stock Company will host a conference call and webcast today at 8:00 am ET GAITHERSBURG, Md., Aug. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced financial results for the second quarter ended June 30, 202

    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PHGE
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more